# V-Bio Ventures

> V-Bio Ventures is a VC fund in Gent backing Biotechnology and Health Care. See 44 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Gent, Belgium
- Total investments: 44
- Last investment: Oct 2025
- Lead investor: 34%
- Fund size: $129M
- Last fund: Mar 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/v-bio-ventures
- Website: http://v-bio.ventures

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

## Contacts

5 contacts available for V-Bio Ventures. Shizune tracks 4 team members at V-Bio Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/v-bio-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $3.1M–$50M |
| Series A | $6.6M–$70M |
| Series B | $12M–$88M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 16 | 36% |
| Health Care | 11 | 25% |
| Therapeutics | 9 | 20% |
| Medical | 8 | 18% |
| Pharmaceutical | 5 | 11% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 20 | 45% |
| Series B | 9 | 20% |
| Seed | 6 | 14% |
| Funding Round | 4 | 9% |
| Series C | 2 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 13 | 30% |
| France | 4 | 9% |
| United States | 2 | 5% |
| United Kingdom | 2 | 5% |
| Italy | 1 | 2% |

7 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Shelley Margetson | Managing Partner | 1 | https://shizune.co/investors/profile/shelley-margetson |
| Willem Broekaert | Managing Partner | 1 | https://shizune.co/investors/profile/willem-broekaert |
| Christina Takke | Managing Partner | 3 | https://shizune.co/investors/profile/christina-takke |
| Ward Capoen | Partner | 8 | https://shizune.co/investors/profile/ward-capoen |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Step Pharma | Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M | Series C | Oct 15, 2025 |  |
| Animab | Animal Health Company | $11.8M | Series B | Jul 01, 2025 |  |
| RootWave | RootWave is an electronics company that develops tools that kill weeds it enables farmers to control weeds on their farm. Its technology is an alternative substitute for herbicides and other weed control chemicals. The company was founded in 2012 and headquartered in Warwickshire, United Kingdom. | $12M |  | Jun 10, 2025 |  |
| Avidicure | Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.“AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology. | $50M | Seed | Apr 24, 2025 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M | Series A | Mar 24, 2025 |  |
| ATB Therapeutics | ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. | $57.2M | Series A | Nov 18, 2024 |  |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M | Series A | Jun 26, 2024 |  |
| Biodol Therapeutics | Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics. | $7.6M |  | May 21, 2024 |  |
| Flindr Therapeutics | Immagene develops personalized cancer immunotherapies to fight multiple cancer type. | $21.4M | Series A | Apr 24, 2024 |  |

10 of 44 investments shown.

## Co-investors
- [VIB](https://shizune.co/investors/profile/vib) — VC Fund, 14 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 12 deals together
- [Agri Investment Fund](https://shizune.co/investors/profile/agri-investment-fund) — VC Fund, 9 deals together
- [Gemma Frisius Fund](https://shizune.co/investors/profile/gemma-frisius-fund) — VC Fund, 8 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 7 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)

## FAQ

### What does V-Bio Ventures invest in?

V-Bio Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is V-Bio Ventures's check size?

V-Bio Ventures typically joins rounds of $3.1M–$50M at Seed, $6.6M–$70M at Series A and $12M–$88M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds V-Bio Ventures participates in.

### How do I contact V-Bio Ventures?

Public channels for V-Bio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at V-Bio Ventures?

The team at V-Bio Ventures includes Shelley Margetson (Managing Partner), Willem Broekaert (Managing Partner) and Christina Takke (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co